olfactory receptor family 4 subfamily F member 15Genealiases: []
Q-omics provides the consensus-scored OR4F15 profile across patient tissues and cancer cell-line models. OR4F15 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, OR4F15 is differentially expressed in 3, with the highest sampling consensus in KIRC. Additionally, OR4F15 RNA expression shows 10,865 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight THCA, KIRC, and UVM as cancer lineages where OR4F15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR4F15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR4F15 survival associations across molecular data types. OR4F15 RNA expression shows survival associations in the most cancer types (12), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR4F15 RNA expression–survival associations across cancer types. High OR4F15 expression shows unfavorable associations in THCA, UVM, BLCA, STAD, LGG and SKCM. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for OR4F15 RNA expression.
This table summarizes OR4F15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for OR4F15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR4F15 shows lower tumor expression in BRCA and higher tumor expression in KIRC and KIRP. The KIRC box plot shows higher OR4F15 RNA expression in tumor versus normal tissue (log2 FC = +0.012, t-test p = .004).
This table shows molecular features associated with OR4F15 in patient tissues and cancer cell lines. In patient samples, OR4F15 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, OR4F15 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in SKIN and SOFT_TISSUE.
